Sign in
  • Home
  • News Bytes
  • Lead Story
  • Editor’s Zone
  • Industry Reports
  • Events
  • Expert Column
  • Policy
  • Startup Tracker
  • Face to Face
  • Chat with BioVoice
  • BioVoice eMag
Sign in
Welcome!Log into your account
Forgot your password?
Password recovery
Recover your password
Thursday, May 7, 2026
  • Subscribe
  • SUBSCRIBE
  • Write to Us
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
BioVoice BioVoiceNews
wellness India Expo
BioVoice BioVoice
  • Home
  • News Bytes
    • Academia

      Biocon Foundation, in partnership with BeST Cluster and NCBS, onboards first…

      Biotech

      Bayer to offer Eylea 2mg to treat retinal diseases at lower…

      Biosupplier

      Agilent launches a new customer experience center in Mumbai

      Health

      Cardiology experts emphasize early diagnosis amid rising incidence of Bradycardia

      Health

      4baseCare signs MoU with Maharashtra govt to establish Centre of Excellence…

  • Lead Story
    • BioPharma

      Emcure Pharma reduces Poviztra® starting dose price by 55% at Rs…

      Biotech

      India’s bioeconomy set to hit $300B as patent cliff fuels innovation…

      BioPharma

      Biologics, mRNA and Bio Foundries to set the course for pharma’s…

      Diagnostics

      Yoda Diagnostics hosts ‘Yoda Early Mind Summit’ in New Delhi

      Biovoice Shreehas Tambe
      People

      Shreehas Tambe appointed CEO & MD of Biocon Limited, effective April…

  • Editor’s Zone
    • Health Policy

      A Silent Victory: How Uttar Pradesh reversed its Encephalitis crisis

      Policy

      Beyond Trade: How the EU–India FTA reshapes life-sciences industry

      Editor’s Zone

      Safeguarding Our Healers – India’s Doctors Need Protection

      Editor’s Zone

      Lost in Translation? India’s Biologics R&D Shortfall

      Editor’s Zone

      Bridging Science and Business: The Missing Link in Bioscience Innovation

  • Industry Reports
    • Industry Reports

      India Biotech Outlook 2025: The India Advantage at BIO Boston 2025

      Industry Reports

      Inviting your participation in the upcoming India MedTech Handbook 2024

      Industry Reports

      BioVoice News & ICPA team presents India MedTech Handbook 2023 to…

      MedTech

      India MedTech Handbook 2023 launched at the MedTech Conference in USA

      MedTech

      Releasing Soon: India MedTech Handbook 2023 powered by ICPA & BioVoice…

  • Events
    • video
      Events

      Digitalization has democratized healthcare: Experts at BioVoice News e-Conference

      Events

      BioVoice News to host e-Conference on India’s roadmap to Digital Healthcare…

      video
      Events

      Digitally powered smart labs are the future of biopharma R&D: Experts

      Events

      BioVoice News to organize e-Conference on ‘Digital Laboratories: The Emerging Era…

  • Expert Column
    • Expert Column

      Reimagining preventive medicine through genomics, AI, and early risk detection

      Expert Column

      Early cancer detection begins with getting the first step right

      Expert Column

      Leveraging AI to Strengthen India’s Healthcare System

      Expert Column

      The Rise of HealthTech Startups: Innovations Shaping the Future of Medicine

      Expert Column

      How India is Countering the Growing Challenge of Drug-Resistant TB

  • Policy
    • Health Policy

      TB survivors seek govt clarification on continuity of TB medicines &…

      Events

      BioAsia 2026 positions Telangana as a global TechBio powerhouse

      AgriPolicy

      Budget 2026 charts a technology-led path for Indian agriculture

      Health

      Budget 2026: Healthcare skill development & medical tourism gets due attention

      BioPolicy

      Telangana sets global ambition with next generation life sciences policy 2026–30

  • Startup Tracker
    • Startup Tracker

      IIIT Hyderabad incubated biotech startup BioReform bags global award for ditching…

      Startup Tracker

      Gut Clinic raises $1 million in seed round to build India’s…

      Startup Tracker

      IAN Alpha Fund co-leads ₹70 Cr Series A funding round in…

      Biovoice News invests
      Startup Tracker

      Pandorum Technologies raises US$18 Million in Series B to advance global…

      Startup Tracker

      4baseCare raises Rs 90 Cr in Series B first close led…

  • Face to Face
    • Face to Face

      “Research must be designed for translation, not just for publications”: Dr…

      video
      Face to Face

      Face to Face with BioVoice News: Dr Sajeev Nair, Founder &…

      video
      Face to Face

      FACE TO FACE: Dr Taslimarif Saiyed, Director and CEO, Centre for Cellular…

      video
      Face to Face

      FACE TO FACE: Harish Bisam, Founder & MD, Bisam Pharmaceuticals

      video
      Face to Face

      FACE TO FACE: Dr Pawan Dhar, Executive Director, CVJ Centre for…

  • Chat with BioVoice
    • Chat with BioVoice

      “Biologics and biosimilars represent Veeda’s second-highest strategic priority after clinical trials”

      Chat with BioVoice

      “AI’s biggest contribution in cardiac monitoring is its speed and efficiency”

      Chat with BioVoice

      “Our focus is on identifying biological mechanisms that may offer alternative…

      Chat with BioVoice

      “We plan to invest Rs 50 crore in phase for R&D…

      Chat with BioVoice

      “Merck has made significant efforts to strengthen lab solutions and R&D…

  • BioVoice eMag
    • BioVoice eMag

      BioVoice eMagazine November 2025 | Issue 10 | Volume 6

      BioVoice eMag

      BioVoice eMagazine October 2025 | Issue 9 | Volume 6

      BioVoice eMag

      BioVoice eMagazine September 2025 | Issue 8 | Volume 6

      BioVoice eMag

      BioVoice eMagazine July-August 2025 | Issue 7 | Volume 6

      BioVoice eMag

      BioVoice eMagazine June 2025 | Issue 6 | Volume 6

Home Health Clinical Research Veeda Group rebrands as Veeda Lifesciences
  • Health
  • Clinical Research
  • Lead Story
  • Top News

Veeda Group rebrands as Veeda Lifesciences

Veeda Lifesciences represents the brand that integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India

By BioVoice News Desk -
January 3, 2025
0
300
Share on Facebook
Tweet on Twitter
New Delhi: Veeda Group has unveiled a new logo and brand identity—Veeda Lifesciences—marking a key milestone in its journey. The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise for different modalities of drugs including generics and novel chemical and biological entities.
Veeda Lifesciences will operate through four Strategic Business Units: Clinical Trials, Healthy Volunteer Services, Biopharma Services, and Preclinical & Non-Clinical Testing Services, making Veeda an integrated research service provider.
Veeda Lifesciences represents the brand that integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India, showcasing our research services across various stages of the drug development value chain from discovery and preclinical to late-phase development. Our new identity reflects the transition from generics to innovation, local to global, and small molecules to biologics. We are transitioning to a CRO-CDMO model, while leveraging AI & Real-world data.
Dr Mahesh Bhalgat, Group CEO and Managing Director of Veeda Lifesciences, stated, “The name – Veeda Lifesciences – and the new logo, designed to be modern and dynamic, symbolize the Group’s forward-thinking approach and dedication to its core values and mission. It adds aspirational value to our growth and vision for the future, striving for innovation, excellence, and client satisfaction. We continue to diversify our base offering services serving the growing needs of our clients.”
Founded in India in 2004, Veeda Lifesciences now operates out of 5 countries while conducting trials in 26 geographies. The strategic acquisition of Bioneeds in 2021 expanded Veeda into preclinical services. Today, Veeda Lifesciences offers a broad range of services to the life sciences and healthcare industries, with reputable sponsors, including leading global pharma companies. Veeda Lifesciences is now organized under four strategic business units. The Clinical trials business comprises of Veeda’s operations in Europe (originally Health Data Specialists) and patient-based clinical trials in India.
The Healthy Volunteer Services includes operations in Gujarat (India) including clinical bioanalysis for small molecules. The Biopharma services in Bengaluru (India) include analytical characterization and functional characterization of biologics along with cell line and process development and clinical bioanalysis of large molecules. The preclinical testing services of Veeda, based in Karnataka (India) includes our discovery research services in the area of chemistry and biology.

VIABioVoice New Delhi Bureau
  • TAGS
  • Bioneeds
  • Brand
  • Clinical research
  • CRO
  • Group
  • Health Data
  • India
  • Lifesciences
  • Logo
  • Specialists
  • Veeda
Previous article12-month diagnosed prevalent cases of severe asthma to reach 1.89 million in 2033: GlobalData
Next articleIIT Guwahati researchers develop innovative injectable hydrogel for targeted breast cancer therapy
BioVoice News Desk

RELATED ARTICLESMORE FROM AUTHOR

Academia

Biocon Foundation, in partnership with BeST Cluster and NCBS, onboards first BioWISE cohort of Postgraduate Women Students

Biotech

Bayer to offer Eylea 2mg to treat retinal diseases at lower cost in India

Biosupplier

Agilent launches a new customer experience center in Mumbai

Face to Face

Face to Face

“Research must be designed for translation, not just for publications”: Dr...

Rahul Koul - December 18, 2025
336
Dr Sagar Sengupta, Director, National Institute of Biomedical Genomics (NIBMG) and Director (Additional Charge), National Brain Research Centre (NBRC) shared his insights on the latest initiatives, importance of industry-academia collaboration, increased government funding, and evolution of research ecosystem

e-Conference

https://www.youtube.com/watch?v=Nku-bLFGpBI&t=491s

Subscribe Our Newsletter


Chat with BioVoice

Chat with BioVoice

“Biologics and biosimilars represent Veeda’s second-highest strategic priority after clinical trials”

Rahul Koul - February 26, 2026
168
Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans

“AI’s biggest contribution in cardiac monitoring is its speed and efficiency”

January 28, 2026

“Our focus is on identifying biological mechanisms that may offer alternative...

January 19, 2026

R&D

BioPolicy

DBT & BIRAC host webinar on biomanufacturing & biofoundry initiative on...

R&D

New magnetic nanoparticles may help treat cancer

Events

Industry Reports

India Biotech Outlook 2025: The India Advantage at BIO Boston 2025

Events

BioAsia 2025: C4IR Telangana & WEF to spearhead high-level dialogues on...

Events

Countdown begins to BioAsia 2025: A unique platform to showcase startup...

AgriPolicy

NDFC(I) inaugurates 2nd edition of MEWA India 2025

BioVoice
ABOUT US
Welcome to BioVoice News, India’s leading bioscience B2B media network. It serves as credible go-to source for the latest news, insights, interviews and analysis from the dynamic worlds of BioTech, HealthTech and AgriTech. Read More
Contact us: connect@biovoicenews.com
FOLLOW US
  • Terms of Use
  • Privacy
  • Advertise
  • Contact
© Copyright © 2022-2025 BioVoiceNews.com All rights reserved.